跳到正文
原文
MedPage Today·· 2 小时前精选AI 评分75

某药联合化疗在一线治疗胰腺癌中显示潜力

'Grand Slam' Pancreatic Cancer Drug Shows Promise as First-Line Treatment

AI 导读

一项早期临床试验显示,某药(daraxonrasib)联合化疗在一线治疗转移性胰腺癌中的客观缓解率为61%,包括8.2%的完全缓解。然而,该研究规模较小且无对照组,需更多数据验证。

推荐理由

初步结果显示某药联合化疗在一线治疗胰腺癌中的有效率较高,但需更多数据验证。

正文

— Response rate with daraxonrasib plus chemotherapy was 61% in early-stage trial

November 20, 2026 • 3 min read

  • The first-in-class RAS inhibitor daraxonrasib doubled survival in patients with previously treated metastatic pancreatic cancer in a prior phase III trial.
  • In a phase I/II study in the first-line setting, the confirmed objective response rate with daraxonrasib plus chemotherapy was 61%, including 8.2% with a complete response.
  • These results may be "transformative" for the first-line treatment of metastatic pancreatic cancer if confirmed in a phase III trial, the study investigator said.

The first-in-class RAS inhibitor daraxonrasib (Rasonque) in combination with chemotherapy showed promise as a first-line treatment for patients with metastatic pancreatic adenocarcinoma (PDAC), according to results from an early-stage trial.

Among 61 patients, the confirmed objective response rate with daraxonrasib plus gemcitabine and nab-paclitaxel (Abraxane) was 61% (including 8.2% with a complete response), with a median duration of response of 11.1 months, reported Wungki Park, MD, of Memorial Sloan Kettering Cancer Center in New York City.

Median progression-free survival (PFS) was 12.8 months, with a 12-month PFS rate of 51.7%. The overall survival (OS) rate at 12 months was 76.6%.

"This represents a potentially transformative advance in first-line treatment for patients with metastatic pancreatic cancer, already outpacing the high end for the historical overall survival of 8.5 to 11.1 months with conventional chemotherapy," Park said in a press release.

He presented the findings at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain.

"These are very encouraging results in a disease where progress has historically been difficult to achieve," said Shivan Sivakumar, PhD, of the University of Birmingham in England, in comments posted to the Science Media Centre website.

"What is particularly exciting is the potential to move beyond chemotherapy as the mainstay of treatment for pancreatic cancer," he added. "By targeting RAS, a fundamental driver of the vast majority of pancreatic cancers, we may be entering an era where molecularly targeted therapies can meaningfully improve outcomes for patients."

However, the findings should be interpreted "carefully" considering this is a relatively small early-stage study without a randomized control group, Sivakumar cautioned. He suggested that if the findings are confirmed in the phase III RASolute 303 trial, "this could represent one of the most significant advances in the first-line treatment of metastatic pancreatic cancer in recent years."

Daraxonrasib, an oral RAS(ON) multi-selective inhibitor targeting GTP-bound mutant and wild-type RAS, doubled OS and PFS in patients with previously treated metastatic PDAC in the phase III RASolute 302 trial. Based on those results, the FDA in August approved the drug for patients who have received at least one prior systemic therapy or who are ineligible for multi-agent systemic therapy, after giving the green light to an expanded access program earlier in the year.

In his presentation, Park noted that current standard-of-care chemotherapy options for the first-line treatment of metastatic PDAC provide limited benefit, with less than half of patients receiving subsequent second-line therapy, "underscoring the need for more effective first-line treatment options."

The RMC-GI-102 platform study is an ongoing phase I/II multicenter trial of patients with RAS-mutant gastrointestinal tumors. The analysis presented here evaluated daraxonrasib and gemcitabine and nab-paclitaxel among patients in the metastatic PDAC cohort.

Patients had a median age of 67, and 59% were men. Just over half (54%) had an Eastern Cooperative Oncology Group performance status of 1, 70% had liver metastases at enrollment, and 57% had stage IV disease at diagnosis.

The patients received 200-mg daraxonrasib, taken orally once a day, plus gemcitabine and nab-paclitaxel given by intravenous injection on days 1 and 15 in 28-day cycles.

Grade ≥3 treatment-related adverse events (TRAEs) were observed in 75% of patients, the most common of which were anemia (33%), fatigue (16%), neutrophil count decreases (16%), rash (13%), and diarrhea (11%). Serious TRAEs occurred in 23% of patients.

Dose modifications due to daraxonrasib-related adverse events occurred in 66% of patients (most frequently due to rash), while treatment discontinuation due to daraxonrasib-related adverse events was infrequent, occurring in just 5% of patients.

来源:MedPage Today · medpagetoday.com